Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase a activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines

Cancer Research

Volumn 59, Issue 1, 1999, Pages 227-233

  Putz, Thomas ^a,b   Culig, Zoran ^a   Eder, Iris E ^a   Nessler Menardi, Claudia ^a   Bartsch, Georg ^a   Grunicke, Hans ^b   Überall, Florian ^b   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL ACTIVATION; CELL ADHESION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0032894222     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Culig, Z., Hobisch, A., Hittmair, A., Peterziel, H., Radmayr, C., Bartsch, G., Cato, A. C., and Klocker, H. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol. Histopathol., 12: 781-786, 1997.
2. Byme, R. L., Leung, H., and Neal, D. E. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br. J. Urol., 77: 627-633, 1996.
3. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. Regulation of prostatic growth and function by peptide growth factors. Prostate, 28: 392-405, 1996.
4. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
5. Ritchie, C. K., Andrews, L. R., Thomas, K. G., Tindall, D. J., and Fitzpatrick, L. A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology, 138: 1145-1150, 1997.
6. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Washington DC), 279: 563-566, 1998.
7. Davis, R. J. MAPKs. new JNK expands the group. Trends Biochem. Sci., 19: 470-473, 1994.
8. Denhardt, D. T. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem. J., 318: 729-747, 1996.
9. Zhu, X., and Liu, J. P. Steroid-independent activation of androgen receptor in androgen-independent prostate cancer: a possible role for the MAP kinase signal transduction pathway? Mol. Cell. Endocrinol., 134: 9-14, 1997.
10. Danesi, R., Nardini, D., Basolo, F., Del Tacca, M., Samid, D., and Myers, C. E. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol. Pharmacol., 49: 972-979, 1996.
11. Lau, Q. C., Brüsselbach, S., and Müller, R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene, 16: 1899-1902, 1998.
12. Scott, J. D. Cyclic nucleotide-dependent protein kinases. Pharmacol. Ther., 50: 123-145, 1991.
13. Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M. J., and Sturgill, T. W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science (Washington DC), 262: 1065-1069, 1993.
14. Sevetson, B. R., Kong, X., and Lawrence, J. C., Jr. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA, 90: 10305-10309, 1993.
15. Graves, L. M., Bornfeldt, K. E., Raines, E. W., Potts, B. C., Macdonald, S. G., Ross, R., and Krebs, E. G. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA, 90: 10300-10304, 1993.
16. Cook, S. J., and McCormick, F. Inhibition by cAMP of Ras-dependent activation of Raf. Science (Washington DC), 262: 1069-1072, 1993.
17. Hordijk, P. L., Verlaan, I., Jalink, K., van Corven, E. J., and Moolenaar, W. H. cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J. Biol. Chem., 269: 3534-3538, 1994.
18. Englaro, W., Rezzonico, R., Durand-Clement, M., Lallemand, D., Ortonne, J. P., and Ballotti, R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J. Biol. Chem., 270: 24315-24320, 1995.
19. Faure, M., and Bourne, H. R. Differential effects on cAMP on the MAP kinase cascade: evidence for a cAMP-insensitive step that can bypass Raf-1. Mol. Biol. Cell., 6: 1025-1035, 1995.
20. Frodin, M., Peraldi, P., and Van Obberghen, E. Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. J. Biol. Chem., 269: 6207-6214, 1994.
21. Calleja, R., Filloux, C., Peraldi, P., Baron, V., and Van Obberghen, E. The effect of cyclic adenosine monophosphate on the mitogen-activated proteinkinase pathway depends on both the cell type and the type of tyrosine kinase-receptor. Endocrinology, 138: 1111-1120, 1997.
22. Sawada, T., Ohmichi, M., Koike, K., Kanda, Y., Kimura, A., Masuhara, K., Ikegami, H., Inoue, M., Miyake, A., and Murata, Y. Norepinephrine stimulates mitogen-activated protein kinase activity in GTI-1 gonadotropin-releasing hormone neuronal cell lines. Endocrinology, 138: 5275-5281, 1997.
23. 2+ transients. Endocrinology, 134: 596-602, 1994.
24. Nakhla, A. M., and Rosner, W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. Endocrinology, 137: 4126-4129, 1996.
25. Okutani, T., Nishi, N., Kagawa, Y., Takasuga, H., Takenaka, I., Usui, T., and Wada, F. Role of cyclic AMP and polypeptide growth regulators in growth inhibition by interferon in PC-3 cells. Prostate, 18: 73-80, 1991.
26. Kozlowski, J. M., Fidler, I. J., Campbell, D., Xu, Z. L., Kaighn, M. E., and Hart, I. R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res., 44: 3522-3529, 1984.
27. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., and Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer, 21: 274-281, 1978.
28. Gleave, M., Hsieh, J. T., Gao, C. A., von Eschenbach, A. C., and Chung, L. W. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
29. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
30. Cohen, P., Peehl, D. M., and Rosenfeld, R. G. The IGF axis in the prostate. Horm. Metab. Res., 26: 81-84, 1994.
31. Rubin, R., and Baserga, R. Insulin-like growth factor-1 receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab. Invest., 71: 311-331, 1995.
32. MacDonald, A., and Habib, F. K. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer, 65: 177-182, 1992.
33. Connolly, J. M., and Rose, D. P. Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. Prostate, 15: 177-186, 1989.
34. MacDonald, A., Chisholm, G. D., and Habib, F. K. Production and response of a human prostatic cancer line to transforming growth factor-like molecules. Br. J. Cancer, 62: 579-584, 1990.
35. Grasso, A. W., Wen, D., Miller, C. M., Rhim, J. S., Pretlow, T. G., and Kung, H. J. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene, 15: 2705-2716, 1997.
36. Ching, K. Z., Ramsey, E., Pettigrew, N., D'Cunha, R., Jason, M., and Dodd, J. G. Expression of mRNA for epidermal growth factor, transforming growth factor-α and their receptor in human prostate tissue and cell lines. Mol. Cell. Biochem., 126: 151-158, 1993.
37. Morris, G. L., and Dodd, J. G. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J. Urol., 143: 1272-1274, 1990.
38. Fong, C. J., Sherwood, E. R., Mendelsohn, J., Lee, C., and Kozlowski, J. M. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylalion, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α. Cancer Res., 52: 5887-5892, 1992.
39. Sherwood, E. R., Van Dongen, J. L., Wood, C. G., Liao, S., Kozlowski, S. M., and Lee, C. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br. J. Cancer, 77: 855-861, 1998.
40. Connolly, J. M., and Rose, D. P. Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line. Prostate, 16: 209-218, 1990.
41. Tillotson, J. K., and Rose, D. P. Endogenous secretion of epidermal growth factor peptides stimulates growth of DU145 prostate cancer cells. Cancer Lett., 60: 109-112, 1991.
42. Connolly, J. M., and Rose, D. P. Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate, 19: 173-180, 1991.
43. Zi, X., Grasso, A. W., Kung, H. J., and Agarwal, R. A flavonoid antioxidant, silymarin, inhibits activation of erbB 1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res., 58: 1920-1929, 1998.
44. Peng, D., Fan, Z., Lu, Y., DeBlasio, T., Scher, H., and Mendelsohn, J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res., 56: 3666-3669, 1996.
45. Limonta, P., Dondi, D., Marelli, M. M., Moretti, R. M., Negri-Cesi, P., and Motta, M. Growth of the androgen-dependent tumor of the prostate: role of androgens and of locally expressed growth modulatory factors. J. Steroid Biochem. Mol. Biol., 53: 401-405, 1995.
46. Schuurmans, A. L., Boll, J., Veldscholte, J., and Mulder, E. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J. Steroid. Biochem. Mol. Biol., 40: 193-197, 1991.
47. Schuurmans, A. L., Bolt, J., and Mulder, E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate, 12: 55-63, 1988.
48. Seternes, O. M., Sorensen, R., Johansen, B., Loennechen, T., Aarbakke, J., and Moens, U. Synergistic increase in c-fos expression by simultaneous activation of the ras/raf/map kinase-and protein kinase A signaling pathways is mediated by the c-fos AP-1 and SRE sites. Biochim. Biophys. Acta, 1395: 345-360, 1998.
49. Lowe, W. L., Jr., Fu, R., and Banko, M. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3′,5′-monophosphate in MCF-7 breast cancer cells. Endocrinology, 138: 2219-2226, 1997.
50. Hafner, S., Adler, H. S., Mischak, H., Janosch, P., Heidecker, G., Wolfman, A., Pippig, S., Lohse, M., Ueffing, M., and Kolch, W. Mechanism of inhibition of Raf-1 by protein kinase A. Mol. Cell. Biol., 14: 6696-6703, 1994.
51. Erhardt, P., Troppmair, J., Rapp, U. R., and Cooper, G. M. Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells. Mol. Cell. Biol., 15: 5524-5530, 1995.
52. Yee, W. M., and Worley, P. F. Rheb interacts with Raf-1 kinase and may function to integrate growth factor-and protein kinase A-dependent signals. Mol. Cell. Biol., 17: 921-933, 1997.
53. Burgering, B. M., de Vries-Smits, A. M., Medema, R. H., van Weeren, P. C., Tertoolen, L. G., and Bos, J. L. Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways. Mol. Cell. Biol., 13: 7248-7256, 1993.
54. Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A. R., Lanfrancone, L., Pelicci, P. G., and Ciardiello, F. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-reccptor. Oncogene, 14: 923-928, 1997.
55. Kimura, G., Kasuya, J., Giannini, S., Honda, Y., Mohan, S., Kawachi, M., Akimoto, M., and Fujita Yamaguchi, Y. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int. J. Urol., 3: 39-46, 1996.
56. Figueroa, J. A., Lee, A. V., Jackson, J. G., and Yee, D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J. Clin. Endocrinol. Metab., 80: 3476-3482, 1995.
57. Connolly, J. M., and Rose, D. P. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate, 24: 167-175, 1994.
58. Iwamura, M., Sluss, P. M., Casamento, J. B., and Cockett, A. T. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate, 22: 243-252, 1993.
59. Pietrzkowski, Z., Mulholland, G., Gomella, L., Jameson, B. A., Wernicke, D., and Baserga, R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res., 53: 1102-1106, 1993.
60. Ciardiello, F., and Tortora, G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin. Cancer Res., 4: 821-828, 1998.